<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392726</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20-7020-20-SMC-LL-CTIL</org_study_id>
    <nct_id>NCT04392726</nct_id>
  </id_info>
  <brief_title>Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)</brief_title>
  <official_title>Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary intention of this study is to determine the diagnostic performance of
      ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease
      (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic
      yield to standard dose chest High-resolution computed tomography (HRCT) and utility for
      follow-up of patients with known DPLD. We will study this hypothesis through the following
      aims:

        1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying
           mosaic attenuation due to air-trapping.

        2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established
           DPLD to identify disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.</measure>
    <time_frame>during the procedure/surgery</time_frame>
    <description>The diagnostic performance will be evaluated according to the biopsy results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD.</measure>
    <time_frame>during the procedure/surgery</time_frame>
    <description>The diagnostic performance will be evaluated according to the biopsy results</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Parenchymal Lung Disease</condition>
  <arm_group>
    <arm_group_label>patients with suspected DPLD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with known DPLD</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known or suspected DPLD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. suspected or known DPLD

          2. referred to DPLD observation

        Exclusion Criteria:

        1. other lung related diseases

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Liran Levy</investigator_full_name>
    <investigator_title>Transplant pulmonologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

